Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C3H5O3.Na |
| Molecular Weight | 112.0598 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C[C@H](O)C([O-])=O
InChI
InChIKey=NGSFWBMYFKHRBD-DKWTVANSSA-M
InChI=1S/C3H6O3.Na/c1-2(4)3(5)6;/h2,4H,1H3,(H,5,6);/q;+1/p-1/t2-;/m0./s1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H5O3 |
| Molecular Weight | 89.07 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9BXC0 Gene ID: 27198.0 Gene Symbol: HCAR1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | PRISMASOL Approved UsePRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances. Launch Date2006 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| 1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient. | 1991 Aug |
|
| Physiology and pathophysiology of organic acids in cerebrospinal fluid. | 1993 |
|
| Intracellular flux analysis applied to the effect of dissolved oxygen on hybridomas. | 1995 Dec |
|
| Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. | 1998 Jun |
|
| The 12,13-diol cyclization approach for a truly stereocontrolled total synthesis of epothilone B and the synthesis of a conformationally restrained analogue. | 2001 May 18 |
|
| Diastereomeric salts of lactic acid and 1-phenylethylamine, their structures and relative stabilities. | 2002 Dec |
|
| 1H and (13)C NMR spectroscopic analysis of human saliva. | 2002 Jun |
|
| RIO: analyzing proteomes by automated phylogenomics using resampled inference of orthologs. | 2002 May 16 |
|
| Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst. | 2003 Dec 12 |
|
| The absolute configuration of 1-carboxyethyl substituents on common hexoses by circular dichroism. | 2003 Jan 2 |
|
| Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31. | 2003 Oct 24 |
|
| In vivo and in vitro nuclear magnetic resonance spectroscopy as a tool for investigating hepatobiliary disease: a review of H and P MRS applications. | 2005 Apr |
|
| Proton MR CSF analysis and a new software as predictors for the differentiation of meningitis in children. | 2005 Jun |
|
| Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition. | 2005 May 9 |
|
| Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise. | 2006 Jan |
|
| Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues. | 2009 Apr 5 |
|
| Characterization of a diverse secretome generated by the mouse preimplantation embryo in vitro. | 2010 Jun 23 |
|
| Perioperative chronic use of statins and the risk of muscle complaints in patients undergoing knee and hip endoprosthesis surgery. | 2010 Mar |
|
| Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. | 2013 Jun |
Sample Use Guides
Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:34 GMT 2025
by
admin
on
Mon Mar 31 17:50:34 GMT 2025
|
| Record UNII |
P2Y1C6M9PS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29730
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB36522
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
867-56-1
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
DTXSID5052830
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
P2Y1C6M9PS
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
C61944
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
100000128870
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
23664767
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
P2Y1C6M9PS
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY | |||
|
212-762-3
Created by
admin on Mon Mar 31 17:50:34 GMT 2025 , Edited by admin on Mon Mar 31 17:50:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
